News and Announcements
Dimerix’s Latest Research Validating the Relevance of DMX Receptor-HIT Technology Published in Scientific Reports Journal
- Published June 13, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Dimerix Limited (ASX: DXB), a clinical-stage biotechnology company discovering and developing new therapeutic treatments identified using its proprietary assay technology today announce the publication of important research by Chief Scientific Advisor, Associate Professor Kevin Pfleger and colleagues in the leading peer reviewed journal Scientific Reports.
KEY TAKEAWAYS:
- Using state-of-the-art CRISPR technology, the team at the Harry Perkins Institute of Medical Research led by Associate Professor Pfleger has developed world first tools for studying functional receptor interactions in real time.
- Validate the relevance of the Dimerix Receptor-Heteromer Investigation Technology platform to monitor receptor complexes by labelling and monitoring endogenous receptors with tags for bioluminescence resonance energy transfer.
- The Receptor-HIT technology was used to identify DMX-200, Dimerix’s lead clinical stage drug development program, in Phase II of trials for the treatment of chronic kidney disease.
Associate Professor Pfleger highlighted that “This work has considerable potential for improving drug discovery and profiling, leveraging both Dimerix’s Receptor-HIT platform and the latest advances in genome editing”.
Dimerix’S CEO Kathy Harrison said: “Validation of the power of platform technologies which rely on analysis in vitro can be challenging. This pivotal piece of work has shown that the relevance of the heterodimers (the core premise of Receptor-HIT technology) can be demonstrated in cells in real time under endogenous promoter conditions, as occurs in the physiological setting.”
Company Updates
Everything is now competing for the same dollar
Key takeaways As recently as 2022, Germany and Japan could borrow for 30 years at close to zero. That world is gone, and AI is now bidding for what is left. Over the past fortnight, I listened to founders, operators and allocators describe where their industries are heading. They covered four very different frontiers. Each […]
Australia has not held 90 days of fuel since 2012. The fix may start at a sewage plant.
A decommissioned council treatment site in Bundaberg is being built into a $188.9 million biorefinery. Its managing director is candid that the largest revenue line is not yet contracted. Australia has not met its international 90-day fuel reserve obligation since 2012. Around 90 per cent of the country’s liquid fuel is imported. Andy Whitmore, Managing […]
Forget Startups: Why Magnetic Alliance is Betting on “Boring” Mid-Market Turnarounds
While Australia’s venture capital scene spent years chasing unprofitable tech startups and speculative high-growth plays, Mark Lim was quietly taking a radically different path. The Managing Partner of Magnetic Alliance Capital sees the nation’s richest investment opportunities hiding in plain sight: inside thousands of unglamorous, profitable, but operationally sluggish mid-market businesses. Speaking on Wholesale Investor’s […]
Backed By Leading Investment Groups and Family Offices
